Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
about
Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillationAtrial fibrillation in congestive heart failure.The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation.Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures.Cost considerations in the management of atrial fibrillation - impact of dronedarone.Costs and clinical consequences of suboptimal atrial fibrillation management.Cost of atrial fibrillation: invasive vs non-invasive management in 2012Design and rationale of the PRAGUE-12 trial: a large, prospective, randomized, multicenter trial that compares cardiac surgery with left atrial surgical ablation with cardiac surgery without ablation in patients with coronary and/or valvular heart dA multidisciplinary atrial fibrillation clinic.Mechanisms of arrhythmias and conduction disorders in older adults.Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation.Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease.Direct vitamin K antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation.Pulmonary vein isolation for the treatment of atrial fibrillation: past, present and future.Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control?Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes.Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.Cost-of-illness studies of atrial fibrillation: methodological considerations.Bridging the gender gap in atrial fibrillation.Demographics, treatment and outcomes of atrial fibrillation in a developing country: the population-based TuRkish Atrial Fibrillation (TRAF) cohort.Is Helicobacter pylori a cause of atrial fibrillation?A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada.Comparative persistence on β-blockers versus calcium channel blockers for ventricular rate control in nonelderly patients with atrial fibrillation.Risk of kidney injury following cardioversion for atrial fibrillation.Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation.Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.California study of Ablation (CAABL):early utilization after index hospitalization for non-valvular atrial fibrillation.Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation.Burden of comorbidities among patients with atrial fibrillation.Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
P2860
Q33553902-3C3C95B2-86DA-4B88-8405-5616A65DC05CQ33585592-34466518-5512-46F0-A70F-68F481938826Q33714864-671BF0C1-C823-4152-9BAA-2B12D3AE5A66Q33954432-4A5636C1-54FC-490D-8565-9BC50318529DQ34915626-2E05C8DC-A400-458B-A15A-4724082D863AQ35021968-F660AF91-5F59-4F9D-88D2-5C90E2133694Q35225444-0B9EE961-101B-4C20-96DD-1088A2D21E55Q35672289-3E3A068C-BA68-4343-A395-E11092C2C070Q35832134-597748C1-6773-4F72-9940-D738EEC02027Q35885128-5709A210-D230-417C-8CBB-E87EC87577C6Q36382393-8A4CCEB0-7AF4-432B-840D-FDF4FADED64EQ36587561-8A088DEB-25E3-4B7C-BD26-3E96031DA7A3Q36644851-7692D5AE-650A-4AD6-A16C-36B3FD181D9AQ36723709-08A7B00B-E839-4E40-A64F-EE1D8A77E09CQ37020949-4379C138-99DE-4185-B970-040790755497Q37115706-2A1F4B29-3711-496A-8AB7-B14287AA0299Q37556687-C5F1B91C-E704-4D88-AA34-9428C1111843Q37656335-4CF0C321-C5C2-42B7-BBA1-F5F012CFD60AQ37811048-20CBFE11-2D09-4F8A-B443-FE86AAF7FC12Q37812344-32335FAE-9344-437B-A786-2A8AA41568FCQ38155933-8BC0B6F2-96B2-4E99-A5B9-610493D47BDEQ38232326-E61BB273-BFF5-49FE-AA40-BF611066D497Q38317687-17283571-510C-4630-9D44-FF4C839A19DBQ38967685-D5BA0D69-E62E-43B6-B9A3-26C71502C3CAQ40311508-02C57BAF-17B3-473F-906B-E3E3A43D6905Q41205797-ED7879EC-F0CF-4C58-A98E-866296FA3CA5Q43654157-BC716790-58A1-4E96-9F23-64343CB3E5F3Q44367110-F00FF9E1-9F6B-457E-A275-688658440F9AQ45893042-9BE857B5-E2A0-4B80-8319-C99C3889DE68Q46306071-B4FE17DE-F400-4F7C-9004-CF81041C2C5FQ47098949-D2FF8B48-0767-4822-B730-1DDCBF33F238Q47429801-62F28FA8-CE67-431A-A67F-05BC202D5AA9Q51033053-69FC218C-9574-4FC2-8595-7F260D35AD05Q51114477-6BC82097-6715-47BA-9574-50299FC0EC37Q51196111-86A33B3B-CA63-4C6D-B132-0E69DD3084AAQ51833841-8665D723-A947-47D6-B7AD-0D715DBF4404
P2860
Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Economic burden and co-morbidi ...... privately insured population.
@en
Economic burden and co-morbidi ...... privately insured population.
@nl
type
label
Economic burden and co-morbidi ...... privately insured population.
@en
Economic burden and co-morbidi ...... privately insured population.
@nl
prefLabel
Economic burden and co-morbidi ...... privately insured population.
@en
Economic burden and co-morbidi ...... privately insured population.
@nl
P2093
P356
P1476
Economic burden and co-morbidi ...... privately insured population.
@en
P2093
Adam R Castor
Edward Tuttle
Howard G Birnbaum
Jeremy Ruskin
Milena Mareva
Warren Jackman
P304
P356
10.1185/030079905X65475
P407
P50
P577
2005-10-01T00:00:00Z